MEG
AVXL icon

Millstone Evans Group’s Anavex Life Sciences AVXL Stock Holding History

Millstone Evans Group’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.77K Hold
3,000
– – ﹤0.01% 620
2026
Q1 		$9.21K Hold
3,000
– – 0.01% 577
2025
Q4 		$10.7K Hold
3,000
– – 0.01% 543
2025
Q3 		$26.7K Hold
3,000
– – 0.02% 419
2025
Q2 		$27.7K Buy
+3,000
New +$25.6K 0.02% 404

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millstone Evans Group's AVXL Position: Q2 2026 in Review

Millstone Evans Group held its Anavex Life Sciences (AVXL) position steady in Q2 2026 at 3,000 shares worth $7.77K. The position accounts for ﹤0.01% of the portfolio, ranked #620.

Millstone Evans Group first reported a position in AVXL in Q2 2025 and has held it in 5 quarters since. The position peaked at $27.7K in Q2 2025. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Millstone Evans Group held 3,000 shares of Anavex Life Sciences worth $7.77K as of Q2 2026.
  • Millstone Evans Group left its Anavex Life Sciences share count unchanged in Q2 2026.
  • Anavex Life Sciences made up ﹤0.01% of Millstone Evans Group's portfolio in Q2 2026, its #620 holding.
  • Millstone Evans Group first reported a position in Anavex Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • Millstone Evans Group's Anavex Life Sciences position peaked at $27.7K in Q2 2025.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Millstone Evans Group's 13F filing for Q2 2026, filed 11 Aug 2026.